Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Merck booked just under $600 million last year ... blood clots in people with end-stage renal disease on dialysis, and a PCSK9 inhibitor called MK-0616 that could provide an oral alternative ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The American College of Cardiology/Association of Black Cardiologists Merck Research Fellowships provide three one-year fellowships in the amount of $100,000 each to be awarded as salary support for ...